Lucid Diagnostics Inc

NASDAQ • Healthcare • Medical Devices • Quote as of 10/23/2026 16:00

Company Profile

IndustryMedical Devices

SectorHealthcare

ExchangeNASDAQ

Market Capitalization83.22 mln

Float160 mln

Earnings Date11/16/2026

Piotroski F-Score

6 / 9

Solid

Beneish M-Score

-1.45

Manipulation likely

Relative Strength

5 / 100

Severely lagging

Debt / Equity

2.28

Very high leverage

Pre-Tax Margin

-960%

Severely loss-making

ROE

-439

Deeply negative

Business Description

Lucid Diagnostics is a New York-based medical diagnostics company focused on reducing deaths from esophageal cancer. Its main offering combines a cell collection device called EsoCheck with a DNA test called EsoGuard, designed to catch early warning signs of esophageal cancer in people who suffer from chronic acid reflux. The company operates as part of the PAVmed group and has been active since 2018.

Key Fundamentals

EPS-0.44

ROE-439

RPS0.04

ROIC-177

ROA-127

Interest Cover-2,816

EBITDA, mln-51.37

EV / EBITDA-2.65

EV / EBIT-2.60

Revenue, mln5.45

EV / Revenue24.97

Quote Details

Last 0.411

Change 0.0833 (25.42%)

Open 0.4341

Volume 109,349,056

Turnover 44,942,464

Average Volume 7,745,359

Financial Ratios

Pre-Tax Profit Margin-960

Leverage Ratio3.56

Current Ratio1.33

Price / Book12.52

Price / Tangible Book12.52

Debt / Equity2.28

Price / Sales19.26

Financial Strength

Altman Z-Score-11.73

Piotroski F-Score 6 / 9

Beneish M-Score-1.45

Short Ratio11.71

Short % of Float9.06

Price Performance & Relative Strength

Period	Price Performance	Relative Strength
1 Week	-14.02%	6 / 100
1 Month	-50.95%	4 / 100
2 Months	-57.6%	6 / 100
6 Months	-61.59%	9 / 100
1 Year	-66.31%	13 / 100